Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.
Illumina Company Profile
President & CEO: Francis deSouza
Ticker symbol: ILMN
Headquarters: San Diego, CA
Illumina employees: 5,500+ globally
Revenues: $2.4 Billion USD in 2016
Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel
Illumina, Henry Ford Health Partner on Genomic Testing for Cardiovascular Patients
The partnership could yield data to support the use of whole-genome sequencing in treating and managing cardiovascular disease, the leading cause of death in the US.
ACMG: Rare Disease Patients in Poor Countries See Benefit from Clinical Whole-Genome Sequencing
Patients in Illumina's global iHope philanthropic clinical WGS program saw changes in their management regardless of whether they lived in wealthy or poor countries.
At ACMG, GUARDIAN Newborn Sequencing Study Reports High Uptake Rate
The researchers have already identified babies with G6PD deficiency who would have been missed by standard newborn screening.
Germline Tests Lack Utility for Black South African Prostate Cancer Patients, JNCCN Study Finds
Due to homogenous data informing germline genetic test development, marketed panels don't provide useful prostate cancer risk assessment to patients of sub-Saharan African ancestry, a study showed.
Most Patients With Inherited Heart Conditions Not Getting Guideline-Backed Genetic Testing
Researchers analyzed electronic health and claims records to discover very low genetic testing rates among patients with five inherited cardiovascular conditions.